Kelun-Biotech grants Harbour rights to anti-PD-L1 antibody | FDA fast-tracks Aravive's recurrent ovarian cancer candidate | Pfizer's lorlatinib granted promising innovative medicine designation
August 21, 2018
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
Kelun-Biotech grants Harbour rights to anti-PD-L1 antibody
Harbour BioMed acquired the rights to Sichuan Kelun-Biotech Biopharmaceutical's anti-PD-L1 antibody A167 outside of greater China. The deal gives Kelun-Biotech up to $350 million from upfront and milestone payments, plus royalties.
BioCentury (8/20) 
LinkedIn Twitter Facebook Google+ Email
Health Care & Policy
FDA fast-tracks Aravive's recurrent ovarian cancer candidate
Aravive Biologics' AVB-S6-500, being developed to treat patients with platinum-resistant recurrent ovarian cancer, received fast-track designation from the FDA. An early-stage trial of the candidate demonstrated favorable safety with no serious adverse events in healthy volunteers.
eMPR (8/20) 
LinkedIn Twitter Facebook Google+ Email
Pfizer's lorlatinib granted promising innovative medicine designation
The European Medicines Agency granted Pfizer's lorlatinib promising innovative medicine status. Lorlatinib is currently under review for patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer who have already received a second-generation ALK tyrosine kinase inhibitor.
PharmaTimes online (UK) (8/21) 
LinkedIn Twitter Facebook Google+ Email
Company & Financial News
Chinese biopharma launches Boston facility
Chinese biopharma Adlai Nortye has expanded into the US with a center in Boston that will focus on creating new cancer treatments. The center will also host clinical stage programs.
BioSpectrum Asia (8/20) 
LinkedIn Twitter Facebook Google+ Email
Principia Biopharma plans to raise up to $86.3M from IPO
An initial public offering has been filed by Principia Biopharma, which aims to raise up to $86.3 million to bring its lead candidate, PRN1008 -- a Bruton's tyrosine kinase inhibitor being evaluated in midstage trials for pemphigus, an autoimmune skin disease, as well as the bleeding disorder immune thrombocytopenic purpura -- into late-stage testing.
FierceBiotech (8/19) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
The BIO Investor Forum, Oct. 17-18 in San Francisco, is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings. Register today!
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Global Developments
Roche's NSCLC therapy approved in China
China's State Drug Administration granted approval to Roche Holding's Alecensa, or alectinib, as monotherapy for the treatment of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. In a late-stage trial, the drug achieved the primary endpoint of improving progression-free survival compared with Xalkori, or crizotinib, and the results helped alectinib get approved.
BioCentury (8/20) 
LinkedIn Twitter Facebook Google+ Email
Theratechnologies seeks EU nod for HIV-1 infection drug
A marketing application was filed in Europe by Theratechnologies for Trogarzo, or ibalizumab-uiyk, for the treatment of adult patients with HIV-1 infection.
Seeking Alpha (8/20) 
LinkedIn Twitter Facebook Google+ Email
Food & Agriculture
India launches research on biotech mosquitoes to fight spread of dengue
The government of India launched an 18-month experimental project of biotech mosquitoes to control the spread of dengue fever. Aedes aegypti mosquitoes will be infected with Wolbachia bacteria, then released into the wild to mate with local mosquitoes and spread the bacteria, which suppresses the transmission of other blood-borne diseases by infected mosquitoes.
The Hindu (India) (8/21) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
EPA receives over 290K comments on 2019 RFS proposed rule
Over 290,000 comments were filed regarding the Environmental Protection Agency's proposed rule for 2019 renewable volume obligations and 2020 RVO for biomass-based diesel under the under the Renewable Fuel Standard. The proposed rule would require 19.88 billion gallons of biofuel to be added into the country's fuel supply next year and would set the 2020 RVO for biomass-based diesel at 2.43 billion gallons.
Ethanol Producer Magazine online (8/20) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Trust ALT for premium refurbished lab equipment and asset management services
We couldn’t be happier to welcome ALT into the BIO Business Solutions family. Founded in 1999 and serving customers in more than 40 countries, ALT is a trusted global partner in premium refurbished lab equipment and asset management services. BIO and state affiliate members can expect significant cost savings and additional program benefits that can help manage the costs of researching early ideas and developing them into promising treatments. See what we have to offer!
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
If you can't make it better, you can laugh at it.
Erma Bombeck,
humorist
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Sarah Hostetler
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information